tirzepatide cardiovascular outcomes study Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

24.57

★★★★☆4.8 (126)

Possible mechanisms of Tirzepatide's cardiovascular benefits

22.27

★★★★★4.9 (98)

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism

25.20

★★★★★5.0 (157)

CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 8 RANDOMIZED CLINICAL TRIALS

20.18

★★★★★4.7 (84)

SUMMIT: Tirzepatide Improves Outcomes and Quality of Life For Patients With HFpEF and Obesity

21.71

★★★★★4.9 (203)

Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology

29.87

★★★★★5.0 (176)

Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky

24.34

★★★★★4.8 (132)